Table 1.
SARS-CoV-2 variants identified in the COVE trial PP set starting after randomization
| Sequence variant | Placebo | mRNA-1273 | Total |
|---|---|---|---|
| n = 14,164 | n = 14,287 | n = 28,451 | |
| COVID-19 adjudicated cases, n (%) | 769 | 56 | 799 |
| Epsilon, Gamma and Zetaa | 18 (2.3) | 3 (5.4) | 21 (2.6) |
| Epsilon and Gammab | 16 (2.1) | 3 (5.4) | 19 (2.4) |
| Zetac | 2 (0.3) | 0 | 2 (0.3) |
| Epsilon variants detected in California | 15 (2.0) | 3 (5.4) | 18 (2.3) |
| B.1.429 | 9 (1.2) | 3 (5.4) | 12 (1.5) |
| B.1.427 | 6 (0.8) | 0 | 6 (0.8) |
aEpsilon B.1.427 and B.1.429 (formerly considered VOCs at the time of sequencing) first detected in California, Gamma P.1 (originally VOI at the time of sequencing) and Zeta P.2.
bIncludes Gamma P.1 (one (0.1)) in mRNA-1273.
cZeta P.2. Variants categorized according to CDC (https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html#Concern).